Aurobindo One Step Closer To Xolair Biosimilar Registration
Subsidiary CuraTeQ Completes Phase I Trial With Primary Endpoints Achieved
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
